Your browser doesn't support javascript.
Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic.
Morgan, Camille E; Rimland, Casey A; Bell, Griffin J; Kim, Min K; Hedrick, Tanner; Marx, Ashley; Bramson, Brian; Swygard, Heidi; Napravnik, Sonia; Schmitz, John L; Carson, Shannon S; Fischer, William A; Eron, Joseph J; Gay, Cynthia L; Parr, Jonathan B.
  • Morgan CE; Medical Scientist Training Program, University of North Carolina at Chapel Hill (UNC), Chapel Hill, NC, USA; Department of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC, USA.
  • Rimland CA; Medical Scientist Training Program, University of North Carolina at Chapel Hill (UNC), Chapel Hill, NC, USA.
  • Bell GJ; Department of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC, USA.
  • Kim MK; Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA.
  • Hedrick T; Department of Pharmacy, UNC Medical Center, Chapel Hill, NC, USA.
  • Marx A; Department of Pharmacy, UNC Medical Center, Chapel Hill, NC, USA.
  • Bramson B; Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA.
  • Swygard H; Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA.
  • Napravnik S; Department of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC, USA; Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA.
  • Schmitz JL; Department of Pathology and Laboratory Medicine, UNC School of Medicine, Chapel Hill, NC, USA.
  • Carson SS; Division of Pulmonary Diseases and Critical Care Medicine, UNC School of Medicine, Chapel Hill, NC, USA.
  • Fischer WA; Division of Pulmonary Diseases and Critical Care Medicine, UNC School of Medicine, Chapel Hill, NC, USA.
  • Eron JJ; Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA.
  • Gay CL; Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA.
  • Parr JB; Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA. Electronic address: jonathan_parr@med.unc.edu.
Healthc (Amst) ; 9(4): 100581, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1401487
ABSTRACT
The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 (COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients with a hyperinflammatory state. To inform our local treatment algorithms in the absence of randomized clinical trial results, we performed a rapid analysis of the first 11 hospitalized COVID-19 patients treated with tocilizumab at our academic medical center. We report their early clinical outcomes and describe the process by which we assembled a team of diverse trainees and stakeholders to extract, analyze, and disseminate data during a time of clinical uncertainty.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Healthc (Amst) Year: 2021 Document Type: Article Affiliation country: J.hjdsi.2021.100581

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Healthc (Amst) Year: 2021 Document Type: Article Affiliation country: J.hjdsi.2021.100581